8/25/2005 12:50:33 PM ET


    SWISS MEDICA ANNOUNCES INSIDER BUYING PLAN
      
    FOR IMMEDIATE RELEASE

    Stock Symbol: OTC BB: SWME
    Aug 25, 2005

    SWISS MEDICA ANNOUNCES INSIDER BUYING PLAN

    TORONTO-Swiss Medica, Inc. (OTCBB: SWME) is pleased to announce that Swiss Medica’s senior management
    team and members of Swiss Medica’s Board of Directors intend to purchase on the open market, shares of the
    Company's publicly traded Class A common stock, based on their assessment of prevailing market prices.
    Whether any such purchases are made, and the number of shares purchased, will depend upon the availability
    of shares at acceptable market prices. All trades will comply with Swiss Medica’s insider trading policy and
    insiders will file Form 4s with the S.E.C. as purchases are completed.

    Mr. Raghu Kilambi, Swiss Medica’s CEO commented, “At current levels, we believe our stock is undervalued.
    These planned open market purchases illustrate our confidence in Swiss Medica’s underlying business strategy.”

    About Swiss Medica, Inc.

    Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our
    market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a
    world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please
    visit our websites at www.swissmedica.com, www.O24zone.com and www.pmsescape.com

    Swiss Medica's flagship product, the O24™ Pain Neutralizer, holds US Patent #6,444,238B1. The O24™ pain
    relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by
    healthcare professionals and athletes in the United States, Canada and in Europe. O24™ is widely available
    throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit
    www.O24zone.com, for ordering details and store locators for the nearest pharmacy.

    Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS
    Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce
    changes in mood and appetite that women experience during the premenstrual period. Customers can also visit:
    www.pmsescape.com for additional information and ordering details.

    Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United
    States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking
    statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close
    transactions being contemplated, risks related to international sales and potential foreign currency exchange
    fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological
    changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's
    periodic reports filed with the United States Securities and Exchange Commission and other regulatory
    authorities.

    For more information, please contact:

    Swiss Medica Inc.
    Investor Relations Contact:
    David Jones
    (866) 485-4243
    djones@swissmedica.com